Nirogacestat administered at 150 mg twice daily has shown efficacy in a phase 3 study of desmoid tumors (17), but a therapeutic dose of nirogacestat as an adjunct to BCMA-directed therapies in multiple myeloma has not yet been established and may be dependent on the BCMA-targeting agent used in combination. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.